A. Tubaro, M. Niero, B. Adalig, Z. Lulic, Janet Plastino, Carie L. Kimbrough, M. Manyak
{"title":"在初级保健队列中识别良性前列腺增大/梗阻男性的三项筛查工具的评估。","authors":"A. Tubaro, M. Niero, B. Adalig, Z. Lulic, Janet Plastino, Carie L. Kimbrough, M. Manyak","doi":"10.23736/S0393-2249.20.03834-5","DOIUrl":null,"url":null,"abstract":"BACKGROUND\nBenign prostatic hyperplasia (BPH), a progressive condition and common cause of lower urinary tract symptoms (LUTS), is underdiagnosed in primary care, impacting patient outcomes. Here, we evaluate the utility of a BPH screening tool in general practice, to identify men confirmed to have BPH after urologist assessment of diagnostic test results.\n\n\nMETHODS\nA 3-item questionnaire was developed to discriminate between LUTS due to BPH versus other conditions, and was translated and validated cross-culturally. Its utility was assessed in a cohort study (FDC116114/NCT02757963) conducted in 47 centers across France, Germany, Italy, Russia, and Spain. The study enrolled men ≥50 years of age presenting to general practice clinics with a score of ≥3 on the BPH screening tool or ≥8 on the International Prostate Symptom Score (IPSS). In total, 561 men completed the study. The primary endpoint was the proportion of patients with a urologist-confirmed BPH diagnosis among those with a positive result on the BPH screening tool (score ≥3) and serum prostate specific antigen (PSA) ≥2ng/mL.\n\n\nRESULTS\nThe primary endpoint was fulfilled; 88.3% (95% CI: 84.9, 91.2) of patients had urologistconfirmed BPH diagnoses among those with positive results on the BPH screening tool and serum PSA ≥2ng/mL, similar to the proportion seen with IPSS ≥8 and serum PSA ≥2ng/mL (87.7%; 95% CI 84.6, 90.4).\n\n\nCONCLUSIONS\nThe BPH screening tool, in conjunction with serum PSA, demonstrated adequate predictive value by allowing general practitioners to quickly screen men presenting with different medical conditions but identified as having urological symptoms.","PeriodicalId":49015,"journal":{"name":"Minerva Urologica E Nefrologica","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Evaluation of a 3-item screening tool to identify men with benign prostatic enlargement/obstruction in a primary care cohort.\",\"authors\":\"A. Tubaro, M. Niero, B. Adalig, Z. Lulic, Janet Plastino, Carie L. Kimbrough, M. Manyak\",\"doi\":\"10.23736/S0393-2249.20.03834-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"BACKGROUND\\nBenign prostatic hyperplasia (BPH), a progressive condition and common cause of lower urinary tract symptoms (LUTS), is underdiagnosed in primary care, impacting patient outcomes. Here, we evaluate the utility of a BPH screening tool in general practice, to identify men confirmed to have BPH after urologist assessment of diagnostic test results.\\n\\n\\nMETHODS\\nA 3-item questionnaire was developed to discriminate between LUTS due to BPH versus other conditions, and was translated and validated cross-culturally. Its utility was assessed in a cohort study (FDC116114/NCT02757963) conducted in 47 centers across France, Germany, Italy, Russia, and Spain. The study enrolled men ≥50 years of age presenting to general practice clinics with a score of ≥3 on the BPH screening tool or ≥8 on the International Prostate Symptom Score (IPSS). In total, 561 men completed the study. The primary endpoint was the proportion of patients with a urologist-confirmed BPH diagnosis among those with a positive result on the BPH screening tool (score ≥3) and serum prostate specific antigen (PSA) ≥2ng/mL.\\n\\n\\nRESULTS\\nThe primary endpoint was fulfilled; 88.3% (95% CI: 84.9, 91.2) of patients had urologistconfirmed BPH diagnoses among those with positive results on the BPH screening tool and serum PSA ≥2ng/mL, similar to the proportion seen with IPSS ≥8 and serum PSA ≥2ng/mL (87.7%; 95% CI 84.6, 90.4).\\n\\n\\nCONCLUSIONS\\nThe BPH screening tool, in conjunction with serum PSA, demonstrated adequate predictive value by allowing general practitioners to quickly screen men presenting with different medical conditions but identified as having urological symptoms.\",\"PeriodicalId\":49015,\"journal\":{\"name\":\"Minerva Urologica E Nefrologica\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Minerva Urologica E Nefrologica\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.23736/S0393-2249.20.03834-5\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Minerva Urologica E Nefrologica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.23736/S0393-2249.20.03834-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
背景:良性前列腺增生(BPH)是一种进行性疾病,也是下尿路症状(LUTS)的常见原因,在初级保健中诊断不足,影响患者的预后。在这里,我们评估了BPH筛查工具在一般实践中的效用,以识别经泌尿科医生评估诊断测试结果后确诊患有BPH的男性。方法采用3项问卷对BPH所致LUTS与其他情况下LUTS进行区分,并进行跨文化翻译和验证。在法国、德国、意大利、俄罗斯和西班牙的47个中心进行的队列研究(FDC116114/NCT02757963)中评估了其效用。该研究招募了年龄≥50岁,在全科诊所就诊,BPH筛查工具评分≥3分或国际前列腺症状评分(IPSS)评分≥8分的男性。总共有561名男性完成了这项研究。主要终点是泌尿科医生确诊的BPH诊断患者在BPH筛查工具(评分≥3)和血清前列腺特异性抗原(PSA)≥2ng/mL阳性结果患者中所占的比例。结果主要终点达到;在BPH筛查工具阳性且血清PSA≥2ng/mL的患者中,有88.3% (95% CI: 84.9, 91.2)的患者被泌尿科医生确诊为BPH,与IPSS≥8和血清PSA≥2ng/mL的患者比例相似(87.7%;95% ci 84.6, 90.4)。结论BPH筛查工具,结合血清PSA,显示出足够的预测价值,允许全科医生快速筛查出现不同医疗条件但确定有泌尿系统症状的男性。
Evaluation of a 3-item screening tool to identify men with benign prostatic enlargement/obstruction in a primary care cohort.
BACKGROUND
Benign prostatic hyperplasia (BPH), a progressive condition and common cause of lower urinary tract symptoms (LUTS), is underdiagnosed in primary care, impacting patient outcomes. Here, we evaluate the utility of a BPH screening tool in general practice, to identify men confirmed to have BPH after urologist assessment of diagnostic test results.
METHODS
A 3-item questionnaire was developed to discriminate between LUTS due to BPH versus other conditions, and was translated and validated cross-culturally. Its utility was assessed in a cohort study (FDC116114/NCT02757963) conducted in 47 centers across France, Germany, Italy, Russia, and Spain. The study enrolled men ≥50 years of age presenting to general practice clinics with a score of ≥3 on the BPH screening tool or ≥8 on the International Prostate Symptom Score (IPSS). In total, 561 men completed the study. The primary endpoint was the proportion of patients with a urologist-confirmed BPH diagnosis among those with a positive result on the BPH screening tool (score ≥3) and serum prostate specific antigen (PSA) ≥2ng/mL.
RESULTS
The primary endpoint was fulfilled; 88.3% (95% CI: 84.9, 91.2) of patients had urologistconfirmed BPH diagnoses among those with positive results on the BPH screening tool and serum PSA ≥2ng/mL, similar to the proportion seen with IPSS ≥8 and serum PSA ≥2ng/mL (87.7%; 95% CI 84.6, 90.4).
CONCLUSIONS
The BPH screening tool, in conjunction with serum PSA, demonstrated adequate predictive value by allowing general practitioners to quickly screen men presenting with different medical conditions but identified as having urological symptoms.
期刊介绍:
The journal Minerva Urologica e Nefrologica publishes scientific papers on nephrology and urology. Manuscripts may be submitted in the form of Minerva opinion editorials, editorial comments, original articles, video illustrated articles, review articles and letters to the Editor.